Biotech acquisitions frequently hinge on a single unresolved question: what is a not-yet-approved drug actually worth? The buyer sees risk; the seller sees promise. The contingent value right — CVR — is the instrument that lets a deal close anyway, by splitting the price into a certain amount paid at closing and a conditional amount paid later only if the disputed asset delivers. It is, in effect, a structured bet written into the merger consideration, and its terms are public the moment the deal is filed with the SEC.

Mechanically, a CVR is a non-transferable (sometimes tradable) contractual right issued to the target's shareholders alongside the cash they receive for their shares. The merger agreement defines three things: the trigger (the milestone that must occur — commonly a regulatory approval, a first commercial sale, or net sales crossing a threshold), the amount (a fixed dollar figure per share if the trigger is met), and the deadline (the date by which the milestone must occur or the right expires worthless). Because the contingent amount pays only on success, a CVR lets the buyer hold back part of the price until the uncertainty resolves. A real, SEC-filed deal shows the structure cleanly.

"Novartis to acquire Regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to approximately $1.7 billion."— Regulus Therapeutics Inc., Form 8-K Exhibit 99.1 (filed with the SEC), source

That single sentence is a full CVR teardown. The certain consideration is $7.00 per share in cash, paid at closing. The contingent consideration is an additional $7.00 per share, payable only through the CVR if its milestone is achieved. The headline "up to approximately $1.7 billion" is the sum of both legs — exactly the kind of "up to" figure that, like contingent milestone payments in licensing deals, represents a ceiling rather than committed cash. Here the split happens to be even (half certain, half contingent), which is unusually clean; many biotech CVRs attach a smaller contingent slice to a larger cash base. In every case the disclosure pattern is the same: the certain amount and the contingent amount are stated separately, and the total is the arithmetic of the two.

Why biotech deals use CVRs

The CVR exists to solve a valuation standoff. When most of a target's value sits in an asset whose fate depends on a future regulatory or commercial event, the buyer and seller can hold genuinely different, defensible views of what it is worth. Rather than splitting the difference on a single all-cash number — which forces the buyer to overpay if the asset fails or the seller to undersell if it succeeds — the CVR lets each side be paid according to the outcome. The buyer pays a lower certain price and owes the rest only if its risk view proves wrong; the target's shareholders accept the lower certain price in exchange for keeping the upside if their optimism proves right. The structure converts a disagreement about the future into a conditional payment whose terms both sides can sign today.

For the reader of the filing, the consequence is that a CVR's headline value is not money the holder has — it is an option that may expire at zero. Whether the additional $7.00 per share is ever paid depends entirely on whether the contractually defined milestone is met by the contractual deadline, and the holder bears that risk. That is the same discipline that applies to milestone "biobucks" in licensing: separate the certain leg from the contingent leg, and treat the total only as the best case.

Where the CVR terms are disclosed

The summary terms appear in the deal's 8-K and the accompanying press-release exhibit, as above; the binding mechanics live in the merger agreement and, typically, a separate CVR Agreement filed as an exhibit on sec.gov. That CVR Agreement is where the precise milestone definition, the measurement methodology, the deadline, the diligence obligations of the acquirer (it usually must use defined efforts to pursue the milestone), and any transferability or expiration provisions are set out. The deal also proceeds through the normal change-of-control disclosure machinery — the agreement and plan of merger is itself a material definitive agreement under Form 8-K's Item 1.01 — so the CVR is documented inside a filing the public can pull and read.

A few additional features of CVRs are worth holding in mind when reading the terms. CVRs may be transferable (tradable in the market, so a holder can monetize the right before the milestone resolves) or non-transferable (held until expiry by whoever owned the shares at closing); the agreement specifies which. The milestone definition is frequently the most contested part of the document, because a vaguely drafted trigger invites disputes over whether it was met — which is why CVR agreements typically include precise measurement methodologies, dispute-resolution mechanics, and the diligence standard the acquirer owes (often "commercially reasonable efforts" to pursue the milestone). CVRs have also drawn litigation precisely on that diligence point: holders have sued acquirers alleging they failed to pursue a milestone in good faith. None of that changes the basic read, but it explains why the binding CVR agreement, not the press-release summary, is where the value of the right is actually determined.

The practical takeaway: when a biotech buyout quotes "$X per share plus a CVR worth up to $Y," read the two numbers as distinct instruments. The first is cash on closing. The second is a conditional right whose value is a function of a milestone, an amount, and a deadline — all of which are spelled out in the merger and CVR agreements on sec.gov. The CVR is not a sweetener bolted onto a price; it is the part of the price the buyer agreed to pay only if the future cooperates, and the filing tells you exactly what "cooperates" means.